The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

The purpose of this research study is to find out if the medication known as ketamine can help the symptoms of depression. This drug is approved by the Food and Drug Administration (FDA) but the investigators will use it for a non-FDA approved reason (depression).

Topic Bipolar Disorder Depression

Compound Ketamine

Country United States of America

Visit trial

Trial Details

Trial Number

Sponsors & Collaborators

Mayo Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

National Network of Depression Centers
This company doesn't have a full profile yet, it is linked to a clinical trial.

Papers

Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression
This qualitative study (n=21) uses interviews to characterize participants' experiences of intravenous (IV) ketamine infusions for treatment-resistant depression. 43% of participants had experienced remission. Five of the non-remitters were characterized as having experienced partial recovery based on their subjective experience.

Measures Used

Montgomery-Asberg Depression Rating Scale
A ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.